Cancer firms collaborate over breast cancer treatment
Scandion Oncology and 2curex will get DKK 6 million (USD 905,000) from the EU to optimize the treatment of breast cancer with Scandion's drug candidate.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY CATHERINE BRETT
A pot of gold has been given to Copenhagen-based cancer companies Scandion Oncology and 2curex, which are both listed in Sweden.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
